Table 3.

Significant associations of extra-articular manifestations

	no psoriasis (n=83)	psoriasis (n=43)	p
males (n)	59 (71.1%)	22 (51.2%)	0.027
smoking (n)	18 (21.7%)	16 (37.2%)	0.043
peripheral SpA (n)	54 (65.1%)	39 (90.7%)	0.002
peripheral arthritis (n)	37 (44.6%)	39 (90.7%)	< 0.001
X-ray sacroiliitis (n)	44 (53%)	4 (9.3%)	< 0.001
uveitis (n)	11 (13.3%)	0 (0%)	0.016
NSAIDs (n)	62 (74.7%)	12 (27.9%)	< 0.001
sulfasalazine (n)	46 (55.4%)	10 (23.3%)	0.001
obesity (n)	2 (2.4%)	5 (11.6%)	0.045
age (years)	38 (18)	50 (15)	< 0.001
diagnosis
AS (n)	67 (80.7%)	3 (7%)	< 0.001
PsA (n)	0 (0%)	39 (90.7%)
UDSpA (n)	16 (19.3%)	1 (2.3%)
type of SpA
axial SpA (n)	29 (34.9%)	4 (9.3%)	0.008
peripheral SpA (n)	5 (6%)	4 (9.3%)
mixed SpA (n)	49 (59%)	35 (81.4%)
	no uveitis (n=115)	uveitis (n=11)
males (n)	71 (61.7%)	10 (90.9%)	0.044
psoriasis (n)	43 (37.4%)	0 (0%)	0.016
NSAIDs (n)	64 (55.7%)	10 (90.9%)	0.026
sulfasalazine (n)	47 (40.9%)	9 (81.8%)	0.011
dyslipidemia (n)	42 (36.5%)	1 (9.1%)	0.047
diagnosis
AS (n)	60 (52.2%)	10 (90.9%)	0.037
PsA (n)	39 (33.9%)	0 (0%)
UDSpA (n)	16 (13.9%)	1 (9.1%)
	no dactylitis (n=117)	dactylitis (n=9)
tendinitis (n)	3 (2.6%)	2 (22.2%)	0.041
sulfasalazine (n)	48 (41%)	8 (88.9%)	0.010
infliximab (n)	35 (29.9%)	0 (0%)	0.044
biologics (n)	74 (63.2%)	2 (22.2%)	0.029
fibrinogen (mg/ dL)	285 (139)	372 (203)	0.043
Notes:
- scale variables are reported as “median (intequartile range)”, while nominal variables are reported as “frequency (subgroup percentage)”;
- p values represent the significance of Mann Whitney (scale variables) or χ2 (nominal variables).
Abbreviations: AS = ankylosing spondylitis, NSAIDs = non-steroidal anti-inflammatory drugs, PsA = psoriatic arthritis, SpA = spondyloarthritis, UDSpA = undifferentiated spondyloarthritis.